Congresswoman Questions FDA Decision On Mentor Implant Study
This article was originally published in The Gray Sheet
Executive Summary
Rep. Rosa DeLauro, D-Conn., is questioning FDA's decision in May to allow patients getting Mentor's MemoryGel silicone breast implant to opt out of the firm's 10-year post-approval safety study
You may also be interested in...
House Ag Approps Chair Threatens FDA Management On Safety Role
The chair of the House Appropriations Agriculture Subcommittee is threatening to zero-out salaries of FDA center directors and heads of offices in fiscal 2008 as a consequence of failing to follow through on safety investigations
Silicone Breast Implant Approvals Conditioned On Huge Postmarket Studies
FDA's Nov. 17 approval of silicone-gel breast implants comes with the requirement for one of the largest post-approval studies ever called for by the device center, according to CDRH Director Dan Schultz
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.